DAEJEON, South Korea and NORTH BETHESDA, Md., Oct. 31, 2025 (GLOBE NEWSWIRE) -- IntoCell Inc. (KOSDAQ: 287840), a biotechnology company developing next-generation payload and linker technologies for ...
Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate (ADC) linker platform. The two companies have been working together ...
Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform -- Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ...
Piramal Pharma Solutions has joined forces with IntoCell to broaden its bioconjugates offering and support innovation in the field. Leveraging IntoCell's proprietary drug-linker technologies alongside ...
Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...
Lonza is responsible for manufacturing proprietary tech components and Sidewinder for ADC, R&D, manufacturing, and commercialization.
Antibody-drug conjugates (ADCs) have been in development for decades, but only about a dozen have received FDA approval. Clearly, ADCs still have some major challenges. Yet they have done little to ...
PRAGUE--(BUSINESS WIRE)--SOTIO, a clinical-stage immuno-oncology company owned by PPF Group, today announced a license and option agreement with Synaffix B.V., a Lonza company, to develop ...
Samsung Biologics signed a partnership deal with LegoChem Biosciences focused on the development and production of antibody-drug conjugates (ADCs). Although financial details of the deal weren’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback